Clinical Trials on Aggressive NK Cell Leukemia

Total 4090 results

China Medical University, China

Not yet recruiting

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

PD-1 Antibody | Gastrointestinal Tumours | DC-Cell | NK-Cell
National Cancer Institute (NCI)

Completed

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

Acute Adult T-Cell Leukemia/Lymphoma | Adult T-Cell Leukemia/Lymphoma | Chronic Adult T-Cell Leukemia/Lymphoma | HTLV-1 Infection | Lymphomatous Adult T-Cell Leukemia/Lymphoma | Smoldering Adult T-Cell Leukemia/Lymphoma

United States
University College, London
National Institute for Health Research, United Kingdom

Recruiting

CiproPAL (Ciprofloxacin Prophylaxis in Acute Leukaemia) (CiproPAL)

Acute Lymphoblastic Leukaemia - Category

United Kingdom
Weill Medical College of Cornell University
TG Therapeutics, Inc.

Terminated

Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

Chronic Lymphocytic Leukemia | CLL/SLL | CLL Progression

United States
Mela Osorio Maria Jose
Janssen-Cilag Ltd.

Completed

A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia

CLL

Argentina
Chronic Lymphocytic Leukemia Research Consortium
Celgene Corporation

Unknown

Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia | CLL | Untreated | First-Line | Front-line | Initial Therapy

United States
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Recruiting

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Sezary Syndrome | Chronic Lymphocytic Leukemia | Peripheral T-Cell Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | T-Cell Prolymphocytic Leukemia | B-Cell Prolymphocytic Leukemia

United States
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Leukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Leukemia, Chronic Lymphatic | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | B-Lymphocytic Leukemia, Chronic | Leukemia, Chronic Lymphocytic, B-Cell | Lymphocytic Leukemia, Chronic, B Cell | Lymphocytic Leukemia...

United States
Hebei Senlang Biotechnology Inc., Ltd.
The Second Hospital of Hebei Medical University

Unknown

CAR T Cells for Refractory B Cell Malignancy

B-Cell Leukemia | B-Cell Lymphoma

China
National Cancer Institute (NCI)

Terminated

Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia

T-cell Large Granular Lymphocyte Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Juvenile Myelomonocytic Leukemia | Chronic Lymphocytic Leukemia | Secondary Acute Myeloid Leukemia | Childhood Acute Lymphoblastic Leukemia | Prolymphocytic Leukemia | Hairy Cell Leukemia | Acute Undifferentiated Leukemia | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Childhood Acute Myeloid... and other conditions

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
Shanghai Longyao Biotechnology Inc., Ltd.

Unknown

The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)

B-cell Acute Lymphoblastic Leukemia (B-ALL) | Safety and Efficacy of CD19 UCAR-T Cells

China
National Cancer Institute (NCI)

Recruiting

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Lymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Lymphoid Leukemia | B-Cell Leukemia | Leukemia, Lymphocytic, B Cell | B-Cell Lymphoma | B-All | B-NHL | B-Non Hodgkin Lymphoma | B-precursor ALL

United States
National Cancer Institute (NCI)

Completed

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenstrom... and other conditions

United States
Celgene

Completed

A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma

Peripheral T-cell Lymphoma | Adult T-cell Leukemia-Lymphoma

Japan
First Affiliated Hospital of Wenzhou Medical University
Second Affiliated Hospital of Nanchang University; Hrain Biotechnology Co.,...

Unknown

Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | B-cell Adult Acute Lymphoblastic Leukemia

China
National Cancer Institute (NCI)

Terminated

Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

Recurrent Small Lymphocytic Lymphoma | B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Shenzhen Geno-Immune Medical Institute

Recruiting

CAR-T Immunotherapy Targeting CD19- ALL

B-cell Leukemia

China
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Completed

CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients

B-cell Leukemia

China
University of Nebraska
National Cancer Institute (NCI)

Terminated

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States
University of California, San Diego
Genentech, Inc.

Active, not recruiting

A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP) (GA101 & HDMP)

CLL

United States
AbbVie

Completed

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

Leukemia | Cancer | T-cell Prolymphocytic Leukemia (T-PLL)

United States, Australia, Austria, Finland, France, Germany, Italy, Netherlands, United Kingdom
Shanghai Zhangjiang Biotechnology Limited Company

Suspended

Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia (CLL004)

B-cell Chronic Lymphocytic Leukemia

China
Mundipharma Research Limited

Terminated

Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia

Spain
National Cancer Institute (NCI)

Recruiting

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Lymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Lymphoid Leukemia | B-Cell Leukemia | Leukemia, Lymphocytic, B Cell | B-Cell Lymphoma | B-All | B-NHL | B-Non Hodgkin Lymphoma

United States
University of Miami

Recruiting

Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma

Adult T-cell Leukemia-Lymphoma | ATLL

United States
Merck Sharp & Dohme LLC

Terminated

A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)

Myelodysplastic Syndromes | Chronic Lymphocytic Leukemia | Leukemia, Lymphoblastic, Acute, T-cell | Myelogenous Leukemia
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell... and other conditions

United States, Italy
Washington University School of Medicine
Merck Sharp & Dohme LLC

Withdrawn

Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load

Human T-cell Leukemia Virus Type 1 Infection
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Improving Blood Stem Cell Collection and Transplant Procedures

Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia | Myelodysplastic Syndrome (MDS) | CLL (Chronic Lymphocytic Leukemia) | CML (Chronic Myelogenous Leukemia

United States
National Cancer Institute (NCI)

Completed

AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
AbbVie

Suspended

A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice (REVEAL)

Chronic Lymphocytic Leukemia (CLL)

Israel
AbbVie

Completed

A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). (VENICE II)

Chronic Lymphocytic Leukemia (CLL)

Argentina, Australia, Bulgaria, Hong Kong, Hungary, Mexico, New Zealand, Poland, Russian Federation, Taiwan
Bristol-Myers Squibb

Completed

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Follicular Lymphoma | Chronic Lymphocytic Leukemia | Acute Myelogenous Leukemia | Diffuse Large B-Cell Leukemia

United States
National Cancer Institute (NCI)

Terminated

17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Chongqing Precision Biotech Co., Ltd
Shanxi Bethune Hospital

Recruiting

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

Acute Myeloid Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Refractory Leukemia | Relapse Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.

Active, not recruiting

Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

SenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

China
Celgene

Completed

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

B-cell Chronic Lymphocytic Leukemia

United States, Spain, United Kingdom, Canada, Belgium, Czechia, Hungary, Italy, Poland, Israel, Germany, Ireland, France, New Zealand, Denmark, Australia, Netherlands, Romania, Russian Federation, Sweden, Austria, South Africa, Colo... and more
Onxeo

Completed

A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL

B-cell Chronic Lymphocytic Leukemia

United Kingdom
Abbott
Genentech, Inc.

Withdrawn

Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen

B-cell Chronic Lymphocytic Leukemia
Zhujiang Hospital
Guangdong Zhaotai Cell Bio-tech Co., LTD

Withdrawn

CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma (CAR19T2)

B-cell Acute Lymphoblastic Leukemia | B-Cell Lymphoma, Unspecified

China
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Aggressive Non-Hodgkin... and other conditions

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Active, not recruiting

Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT (MULTIPRAT)

Chronic Lymphocytic Leukemia (CLL) | Acute Lymphoblastic Leukemia (ALL) | Non Hodgkin's Lymphoma

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI); AstraZeneca; Genentech, Inc.; National Institutes...

Active, not recruiting

Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL (AVO)

Chronic Lymphocytic Leukemia (CLL)

United States
AbbVie

Active, not recruiting

Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting

Chronic Lymphocytic Leukemia (CLL)

Austria, Germany, Switzerland
Aptevo Therapeutics

Completed

Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Non-Hodgkin's Lymphoma (NHL)

United States
Kymera Therapeutics, Inc.

Recruiting

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

Solid Tumors | T-cell Prolymphocytic Leukemia (T-PLL) | Non Hodgkin Lymphoma (NHL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-Cell Lymphoma (CTCL) | Large Granular Lymphocytic Leukemia (LGL-L)

United States
French Innovative Leukemia Organisation
University Hospital, Lille

Recruiting

Observatory of Prolymphocytic Leukemia T (T-PLL)

Prolymphocytic Leukemia | T-cell Leukemia

France
Fred Hutchinson Cancer Research Center/University...

Withdrawn

Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital of Anhui Medical University; Henan Cancer Hospital and other collaborators

Recruiting

Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients

Induction Chemotherapy | Acute T-Lymphocytic Leukemia | T-cell Lymphoblastic Lymphoma Leukemia | T-cell/Myeloid Mixed Phenotype Acute Leukemia

China

Clinical Trials on Aggressive NK Cell Leukemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations